Acurx Pharmaceuticals, Inc. (ACXP) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ACXP Insider Trading Activity
ACXP Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $170,000 | 6 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| DELUCCIA ROBERT J | 1 | $50,000 | 0 | $0 | $50,000 | |
| LUCI DAVID P | President and CEO | 1 | $50,000 | 0 | $0 | $50,000 |
| Sailer Carl | director | 1 | $25,000 | 0 | $0 | $25,000 |
| Scodari Joseph C | director | 1 | $25,000 | 0 | $0 | $25,000 |
| DEAN JACK H | director | 1 | $10,000 | 0 | $0 | $10,000 |
| Donohue James J. | director | 1 | $10,000 | 0 | $0 | $10,000 |
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Insider Activity of Acurx Pharmaceuticals, Inc.
Over the last 12 months, insiders at Acurx Pharmaceuticals, Inc. have bought $170,000 and sold $0 worth of Acurx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Acurx Pharmaceuticals, Inc. have bought $159,806 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: DELUCCIA ROBERT J () — $50,000. LUCI DAVID P (President and CEO) — $50,000. Sailer Carl (director) — $25,000.
The last purchase of 49,261 shares for transaction amount of $50,000 was made by LUCI DAVID P (President and CEO) on 2025‑01‑06.
List of Insider Buy and Sell Transactions, Acurx Pharmaceuticals, Inc.
| 2025-01-06 | LUCI DAVID P | President and CEO | 49,261 0.2642% | $1.01 | $50,000 | -58.01% | ||
| 2025-01-06 | DELUCCIA ROBERT J | 49,261 0.2642% | $1.01 | $50,000 | -58.01% | |||
| 2025-01-06 | Sailer Carl | director | 24,631 0.1321% | $1.01 | $25,000 | -58.01% | ||
| 2025-01-06 | Scodari Joseph C | director | 24,631 0.1321% | $1.01 | $25,000 | -58.01% | ||
| 2025-01-06 | Donohue James J. | director | 9,852 0.0528% | $1.01 | $10,000 | -58.01% | ||
| 2025-01-06 | DEAN JACK H | director | 9,852 0.0528% | $1.01 | $10,000 | -58.01% | ||
| 2021-11-23 | Sailer Carl | director | 5,161 0.0628% | $4.84 | $24,979 | -21.67% | ||
| 2021-11-19 | DELUCCIA ROBERT J | 5,034 0.0595% | $4.90 | $24,672 | -24.69% | |||
| 2021-11-19 | LUCI DAVID P | President and CEO | 5,200 0.0602% | $4.80 | $24,960 | -24.69% | ||
| 2021-06-29 | Sailer Carl | director | 12,500 0.1719% | $6.00 | $75,000 | -30.67% |
Insider Historical Profitability
| LUCI DAVID P | President and CEO | 1097458 4.6737% | $424,716.25 | 2 | 0 | <0.0001% |
| DELUCCIA ROBERT J | 1010196 4.3021% | $390,945.85 | 2 | 0 | <0.0001% | |
| Sailer Carl | director | 137183 0.5842% | $53,089.82 | 3 | 0 | <0.0001% |
| Scodari Joseph C | director | 27708 0.118% | $10,723.00 | 1 | 0 | |
| Donohue James J. | director | 22352 0.0952% | $8,650.22 | 1 | 0 | |
| DEAN JACK H | director | 21776 0.0927% | $8,427.31 | 1 | 0 |
Historical Insider Profitability vs. Competitors
$8,253,997 | 122 | -53.40% | $8.67M | |
$296,936 | 37 | -18.12% | $7.14M | |
$383,884 | 32 | -25.10% | $7.07M | |
$95,303,339 | 30 | -13.78% | $10.49M | |
$4,368,362 | 28 | -22.35% | $11.29M | |
$894,733 | 27 | -16.65% | $9.58M | |
$523,320 | 24 | 94.37% | $8.78M | |
$114,371,781 | 18 | -1.31% | $10.62M | |
$29,469,413 | 18 | 30.40% | $10.29M | |
$37,194,483 | 17 | -51.30% | $11.23M | |
$51,865 | 17 | -38.70% | $8.79M | |
$490,284 | 15 | -19.03% | $7.2M | |
$11,777,042 | 10 | -11.94% | $8.73M | |
$8,971,546 | 8 | 6.18% | $9.76M | |
$603,773 | 6 | -56.12% | $6.88M | |
Acurx Pharmaceuticals, Inc. (ACXP) | $149,611 | 4 | -25.43% | $9.09M |
$7,699,992 | 2 | -74.95% | $7.76M | |
$19,863 | 1 | 144.27% | $9.78M | |
$25,173 | 1 | -68.88% | $9.83M |
ACXP Institutional Investors: Active Positions
| Increased Positions | 14 | +58.33% | 316,089 | +24.92% |
| Decreased Positions | 8 | -33.33% | 77,315 | -6.1% |
| New Positions | 6 | New | 176,882 | New |
| Sold Out Positions | 6 | Sold Out | 74,530 | Sold Out |
| Total Postitions | 30 | +25% | 2M | +18.83% |
ACXP Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $219.00 | 2.41% | 529,349 | 0 | 0% | 2024-12-31 |
| Prospect Financial Services Llc | $151.00 | 1.67% | 366,576 | +37,500 | +11.4% | 2025-03-31 |
| Geode Capital Management, Llc | $61.00 | 0.67% | 146,500 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $44.00 | 0.48% | 106,201 | +60,000 | +129.87% | 2024-12-31 |
| Vanguard Capital Wealth Advisors | $28.00 | 0.31% | 67,500 | +67,500 | New | 2025-03-31 |
| Susquehanna International Group, Llp | $20.00 | 0.22% | 48,374 | +48,374 | New | 2024-12-31 |
| State Street Corp | $18.00 | 0.2% | 43,466 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $14.00 | 0.16% | 34,245 | +8,334 | +32.16% | 2025-03-31 |
| Nbc Securities, Inc. | $12.00 | 0.14% | 30,000 | +29,981 | +157,794.74% | 2025-03-31 |
| Virtu Financial Llc | $11.00 | 0.13% | 27,836 | +27,836 | New | 2024-12-31 |